Sangamo Therapeutics (SGMOQ) Total Current Liabilities (2010 - 2025)

Sangamo Therapeutics' Total Current Liabilities history runs 16 years deep, the most recent figure standing at $42.5 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 7.29% year-over-year to $42.5 million in Q4 2025; TTM through Dec 2025 was $42.5 million, a 7.29% decrease from a year earlier, with the FY2025 full-year figure at $42.5 million, down 7.29% from the prior year.
• Total Current Liabilities retreated to $42.5 million in Q4 2025 per SGMOQ's latest filing, from $50.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $136.9 million in Q2 2021 and bottomed at $39.0 million in Q2 2024.
• The 5-year median for Total Current Liabilities is $52.0 million (2023), against an average of $78.4 million.
• Across the five-year window, Total Current Liabilities jumped 114.03% in 2021 and slumped 60.38% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $127.9 million in 2021, then slipped by 12.65% to $111.7 million in 2022, then slumped by 57.27% to $47.7 million in 2023, then declined by 4.04% to $45.8 million in 2024, then declined by 7.29% to $42.5 million in 2025.
• Per Business Quant, the three latest SGMOQ Total Current Liabilities figures stand at $42.5 million (Q4 2025), $50.1 million (Q3 2025), and $47.7 million (Q2 2025).